Rheopheresis for Raynaud's and Digital Ulcers in Systemic Sclerosis
Status:
Not yet recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
In this feasibility study, we aim to explore therapeutic Rheopheresis (RheoP) as a novel
treatment option for SSc-associated Raynaud's phenomenon and/or digital ulcers and compare it
to the standard of care treatment (intravenous iloprost. RheoP has been used for RP/DU with
some success in observational studies, nevertheless, the optimal treatment modality,
duration, or frequency of RheoP (and PEX in general) in SSc has not been established as of
yet.